home / stock / arfxf / arfxf news

ARFXF News and Press, Amorfix Life Sciences Ltd From 04/09/20

Stock Information
Company Name: Amorfix Life Sciences Ltd
Stock Symbol: ARFXF
Market: OTC
Website: promisneurosciences.com
Menu
ARFXF ARFXF Quote ARFXF Short ARFXF News ARFXF Articles ARFXF Message Board
Get ARFXF Alerts

News, Short Squeeze, Breakout and More Instantly...
ARFXF - Journal of the American Academy of Neurology Publishes ProMIS Neurosciences' Abstracts on Novel Antibody Candidates

TORONTO and CAMBRIDGE, Mass., April 09, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers of proteins implicated in the development of neurodegene...
ARFXF - ProMIS Neurosciences to Present Data and Moderate Session at AAIC 2020

TORONTO and CAMBRIDGE, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative disea...

ARFXF - NetworkNewsBreaks - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) Announces Annual Results for Fiscal Year 2019, Approval for Warrant Repricing

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, recently announced its operational and financial results for th...

ARFXF - PROMIS NEUROSCIENCES ANNOUNCES APPROVAL FOR WARRANT REPRICING

/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, March 24, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (“ ProMIS ” or the “ Company ”) (TSX: PMN) (OTCQB: ARFXF) announces that the Company has received app...
ARFXF - ProMIS Neurosciences Announces Fiscal Year 2019 Annual Results

TORONTO and CAMBRIDGE, Mass., March 18, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in th...

ARFXF - ProMIS Neurosciences Initiates Natural History Study of Blood-Based Biomarkers in Alzheimer's Disease

TORONTO and CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), with Toronto Memory Program, Canada’s largest and most experienced memory clinic and site for drug treatment trials in Alzheimer’s disease (AD) has initiated a...

ARFXF - ProMIS Neurosciences Announces Gross Proceeds of $1,257,970 Related to the Exercise of Common Stock Warrants

TORONTO and CAMBRIDGE, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseas...
ARFXF - ProMIS Neurosciences to Participate in Noble Capital Markets 16th Annual Investor Conference

TORONTO and CAMBRIDGE, Mass, Feb. 11, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative disease...

ARFXF - ProMIS Neurosciences to Participate in the BIO CEO & Investor Conference

TORONTO and CAMBRIDGE, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseas...

ARFXF - ProMIS Neurosciences Data for Alzheimer's Disease Program Targeting Tau Accepted for Presentation at Tau2020

TORONTO and CAMBRIDGE, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseas...
Previous 10 Next 10